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L-NAME. Am. J. Physiol. 275 (Renal Physiol. 44): F870–
F877, 1998.—Experimental evidence indicates that the renal
circulation is more sensitive to the effects of nitric oxide (NO)
synthesis inhibition than other vascular beds. To explore
whether in men the NO-mediated vasodilator tone is greater
in the renal than in the systemic circulation, the effects of
three different intravenous infusions of NG-nitro-L-arginine
methyl ester (L-NAME; 1, 5, and 25 µg·kg21 ·min21 for 30
min) or placebo on mean arterial pressure (MAP), systemic
vascular resistance (SVR), renal blood flow (RBF), renal
vascular resistance (RVR), glomerular filtration rate (GFR),
and fractional sodium and lithium excretion (FENa and FELi)
were studied in 12 healthy subjects, each receiving randomly
two of the four treatments on two different occasions. MAP
was measured continuously by means of the Finapres device,
and stroke volume was calculated by a model flow method.
GFR and RBF were estimated from the clearances of radiola-
beled thalamate and hippuran. Systemic and renal hemody-
namics were followed for 2 h after start of infusions. During
placebo, renal and systemic hemodynamics and FENa and
FELi remained stable. With the low and intermediate L-
NAME doses, maximal increments in SVR and RVR were
similar: 20.4 6 19.6 and 23.5 6 16.0%, respectively, with the
low dose and 31.4 6 26.7 and 31.2 6 14.4%, respectively, with
the intermediate dose (means 6 SD). With the high L-NAME
dose, the increment in RVR was greater than the increment
in SVR. Despite a decrease in RBF, FENa and FELi did not
change with the low L-NAME dose, but they decreased by
31.2 6 11.0 and 20.2 6 6.3%, respectively, with the intermedi-
ate dose and by 70.8 6 8.1 and 31.5 6 15.9% with the high
L-NAME dose, respectively. It is concluded that in men the
renal circulation is not more sensitive to the effects of NO
synthesis inhibition than the systemic circulation and that
the threshold for NO synthesis inhibition to produce antina-
triuresis is higher than the threshold level to cause renal
vasoconstriction.
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EXPERIMENTAL STUDIES with L-arginine analogs that
inhibit nitric oxide (NO) synthesis have provided un-
equivocal evidence that NO is an important regulator of
renal blood flow (RBF), diuresis, and natriuresis. Conse-
quently, it has been suggested that disorders in the
NO-forming pathway may be involved in the pathogen-
esis of certain forms of hypertension (9, 19, 28). Dose-
response studies with short-lasting systemic infusions
of the L-arginine analog NG-nitro-L-arginine methyl
ester (L-NAME) in rats have shown that a low degree of
NO synthesis inhibition can evoke a decrease in diure-
sis and natriuresis without affecting RBF (20). At a
somewhat higher degree of NO synthesis inhibition,
RBF decreases as well, whereas a still higher degree of
NO synthesis inhibition is required to induce a rise in
systemic blood pressure. On the basis of these observa-
tions, it has been hypothesized that the kidney is
particularly sensitive to the effects of NO synthesis
inhibition, suggesting a greater NO vasodilator tone in
the renal than in the systemic circulation (20). In this
respect, some caution is required, however, because
studies were performed in anesthetized animals. As
has been shown, anesthesia itself can influence the
hemodynamic responses to NO synthesis inhibition in
the various regional vascular beds (29).
So far, few studies have investigated the effects of
acute systemic NO synthesis inhibition on renal func-
tion and systemic hemodynamics in humans (3, 10, 22,
38). These studies do not allow for a conclusion regard-
ing whether in humans, like in animals, the renal
circulation is particularly sensitive to the effects of NO
synthesis inhibition, since studies comparing the ef-
fects of different degrees of NO synthesis inhibition on
systemic and renal hemodynamics and renal sodium
handling have not been performed. In an attempt to
further clarify this issue, we investigated in healthy
human volunteers the effects of different degrees of
acute systemic NO synthesis inhibition on the above-




Twelve nonsmoking apparently healthy men, who used no
drugs, age 24 6 6 yr (means 6 SD) participated in the study.
Their dietary salt intake was unrestricted. On the evening
before the study day each subject took a single dose of 400 mg
of lithium carbonate. The study protocol was approved by the
Medical Ethics Committee of the University Hospital Di-
jkzigt, and written informed consent was given by all sub-
jects.
Study Protocol
On the study days, the participants arrived at the cardiovas-
cular research unit at 7:30 AM after an overnight fast.
Indwelling catheters were placed in veins of both forearms for
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infusions and blood sampling. All subjects received an initial
load of tap water (12 ml/kg body wt) and, to maintain diuresis,
water input matched urinary output (UV) throughout the
study. The subjects remained supine except when voiding.
Renal clearance studies started at 8:00 AM with an intrave-
nous loading dose of [125I]iothalamate and [131I]orthoiodohip-
puran after which continuous infusion of both tracers was
started (41). After a 60-min equilibration period, the subjects
passed urine to empty the bladder. This was followed by six
30-min clearance periods. The study drug was administered
during the third clearance period. Throughout the study,
finger blood pressure was recorded continuously.
Urine for determination of urine flow rate, tracers, lithium,
sodium, cGMP, and nitrite1nitrate was collected at the end
of each clearance period. Blood samples were drawn at the
end of the clearance periods, and they were analyzed for
tracers, hematocrit, lithium, sodium, L-citrulline, cGMP, and
vasoactive hormones.
Four different conditions were studied. These consisted of a
30-min intravenous infusion of either L-NAME (Clinalpha),
at infusion rates of 1 (n 5 6), 5 (n 5 6), or 25 µg·kg21 ·min21
(n 5 6), or saline (n 5 6).
Each subject was studied two times on different occasions
with an interval of at least 10 days between study days.
Subjects were randomly assigned to the various treatments
with the restriction that they received different infusions on
the two study days.
Methods
Renal function. Glomerular filtration rate (GFR) and effec-
tive renal plasma flow (ERPF) were assessed by calculating
clearances of [125I]iothalamate and [131I]orthoiodohippuran,
respectively. After a loading dose, a continuous constant
infusion technique with timed urine sampling as previously
described was used (41). Effective renal blood flow (ERBF)
was calculated as ERPF/(1 2 hematocrit). Renal vascular
resistance (RVR), expressed in resistance units (RU), was the
ratio between mean arterial pressure (MAP) and ERBF.
Filtration fraction (FF) was calculated as GFR divided by
ERPF. Fractional excretions of sodium (FENa) and lithium
(FELi) were the percentages of filtered sodium and lithium
that were excreted in the urine, whereas filtered sodium and
lithium were calculated as GFR times their plasma concentra-
tions.
Systemic hemodynamics. Finger blood pressure and heart
rate (HR) were recorded continuously with a model 2300
Finapres (Ohmeda, Louisville, CO) and data were stored into
a computer at a sampling frequency of 1,000 Hz. The stored
data were analyzed by the BMI model flow program (TNO,
The Netherlands) to compute beat-to-beat values of MAP, HR,
and stroke volume (SV) (37). Cardiac output (CO) was
calculated as SV times HR. Systemic vascular resistance
(SVR), expressed in resistance units, was calculated as MAP
divided by CO. Averages of the hemodynamic parameters of
the last 10 min of each clearance period were used for
analysis.
Analytical methods. Blood samples for determination of
atrial natriuretic peptide (ANP), endothelin-1, and cGMP
were collected in chilled tubes containing EDTA and aproti-
nin. Samples for determination of renin, norepinephrine,
L-citrulline, and nitrite1nitrate were collected in chilled
heparinized tubes containing glutathione. All samples were
immediately centrifuged at 4°C, and plasma was stored at
280°C. Norepinephrine was measured with fluorometric
detection after HPLC separation (16). Commercially avail-
able kits were used to measure the plasma concentration of
ANP (Nichols Institute, Wijchen, The Netherlands), endothel-
in-1 (Nichols Institute Diagnostics, San Juan Capistrano,
CA), and cGMP (Amersham, Little Chalfont, Buckingham-
shire, UK). Active plasma renin concentration was measured
by an immunoradiometric assay using a commercially avail-
able kit (Nichols Institute Diagnostics). L-Citrulline in plasma
was measured by HPLC with fluorometric detection after
derivatization with O-pthaldialdehyde and 3-mercaptopropi-
onic acid as described (34a). Nitrite1nitrate in urine samples
were measured by capillary electrophoresis with conductivity
detection. The intra- and interassay variation coefficient of
this measurement is 8%. Lithium concentrations in serum
and urine were measured by flame photometry. Sodium in
serum and urine was measured by a routine method at the
Department of Clinical Chemistry of our hospital.
Statistics
Values of ERBF, GFR, RVR, CO, and SVR are expressed
per 1.73 m2 of body surface area. Data are given as mean
values 6 SD in text and in Tables 1–4 and as mean values 6
SE in Figs. 1–3. Baseline values are averages of the data of
the first two clearance periods. A one-way ANOVA was used to
compare the baseline values in the four treatment groups,
whereas a repeated measures ANOVA, followed by Student-
Newman-Keuls multiple comparison test, was used to com-
pare the treatment-induced changes (all time points) in the
four groups. If the Student-Newman-Keuls multiple compari-
son test revealed a significant difference, then Student’s
paired t-test with Bonferroni correction for multiple compari-
sons was used to compare the L-NAME-induced changes vs.
baseline values within one treatment group. P , 0.05 was
considered to indicate a significant difference.
RESULTS
Baseline values of systemic and renal hemodynamics
between the four groups did not differ. Values are given
in Table 1. L-NAME infusions were well tolerated and
side effects were not reported.
Systemic Hemodynamics
MAP, HR, CO, and SVR in the placebo group did not
change throughout the observation period (Fig. 1).
Compared with the time course in the placebo group,
MAP did not rise with the low and the intermediate
Table 1. Baseline values of systemic and renal




n 6 6 6 6
HR, beats/min 59612 56610 5769 59610 0.95
MAP, mmHg 8965 9368 9269 9069 0.86
CO, l/min 6.261.3 5.962.2 6.661.1 5.460.8 0.44
SVR, RU 1563 1866 1463 1762 0.39
GFR, ml/min 105613 11568 114611 11269 0.39
ERBF, ml/min 772677 9446157 8996153 8466148 0.19
RVR, RU 117617 101619 105619 110625 0.57
RBF/CO, l/l 0.1360.04 0.1760.03 0.1460.04 0.1660.04 0.13
Values are means 6 SD; n 5 no. of experiments. HR, heart rate;
MAP, mean arterial pressure; CO, cardiac output; SVR, systemic
vascular resistance; GFR, glomerular filtration rate; ERBF, effective
renal blood flow; RVR, renal vascular resistance; RBF/CO, renal
blood flow vs. cardiac output; L-NAME, NG-nitro-L-arginine methyl
ester; RU, resistance units.
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L-NAME doses. With the high L-NAME dose, MAP rose,
with a maximal increment occurring 60 min after start
of infusion. At that time, MAP had increased by 17.4 6
17.2% (P 5 0.048) compared with baseline.
The L-NAME-induced rise in MAP was caused by a
rise in SVR. With the low, intermediate, and high dose
of L-NAME, the maximal rise in SVR was, respectively,
20.4 6 19.6% (P 5 0.042), 31.4 6 26.7% (P 5 0.002), and
52.9 6 50.1% (P 5 0.027). With the intermediate and
high doses of L-NAME, SVR at the end of the observa-
tion period was still increased in all subjects (Fig. 1).
The already low values of HR tended to decrease
further with the different L-NAME infusions, but the
decrease was significant only with the high dose of
L-NAME (7.8 6 1.8%; P , 0.001).
CO tended to decrease with the low dose of L-NAME.
With the intermediate and high L-NAME dose, CO
decreased significantly by, respectively, 15.9 6 13.0%
(P 5 0.025) and 20.6 6 11.6% (P 5 0.015). Considering
the relatively small decrease in HR, the decrease in CO
was predominantly due to a decrease in SV.
Renal Hemodynamics
Values of ERBF, GFR, RVR, and FF in the placebo
group did not change throughout the observation pe-
riod (Fig. 2). In response to the three L-NAME doses,
ERBF decreased with maximal decrements observed
60–90 min after start of infusions. Compared with
baseline, ERBF decreased maximally by 13.3 6 8.0%
(P 5 0.011) with the low dose, by 18.1 6 5.6% (P 5
0.0006), with the intermediate does, and by 39.5 6 3.9%
(P 5 0.0002) with the high L-NAME dose. Compared
with placebo, RVR increased with the intermediate and
high L-NAME dose (Fig. 2). Compared with baseline,
maximal increments in RVR were 23.5 6 16% (P 5
0.046) with the low dose, 31.2 6 14.4% (P 5 0.005) with
the intermediate dose, and 80.2 6 25.2% (P , 0.001)
with the high L-NAME dose. The ratio of ERBF to CO
did not change with the low and intermediate L-NAME
dose, but it decreased maximally by 22.5 6 11.6% (P 5
0.012) with the high L-NAME dose.
The marked decrements in ERBF were not associ-
ated with parallel decrements in GFR. GFR did not
change with the low and intermediate L-NAME dose
Fig. 1. Time course of changes in mean arterial pressure, heart rate,
cardiac output, and systemic vascular resistance in the 4 treatment
groups. Percentage changes compared with baseline are given.
Placebo (s) or different doses of NG-nitro-L-arginine methyl ester
(L-NAME, r) were administered by intravenous infusion from 0 to 30
min (shaded area). For L-NAME infusion, small solid circles indicate
L-NAME, 1 µg·kg21 ·min21; intermediate solid circles indicate L-
NAME, 5 µg·kg21 ·min21; and large solid circles indicate L-NAME, 25
µg·kg21 ·min21; n.s., not significant.
Fig. 2. Time course of changes in glomerular filtration rate, renal
blood flow, filtration fraction, and renal vascular resistance in the 4
treatment groups. Percentage changes compared with baseline are
given. Placebo (s) or different doses of L-NAME (r, as described in
legend to Fig. 1) were administered by intravenous infusion from 0 to
30 min (shaded area).
F872 L-NAME IN MEN: RENAL AND SYSTEMIC HEMODYNAMICS
and decreased maximally by only 11.7 6 7.2% (P 5
0.012) with the high L-NAME dose. FF increased with
all three doses. The maximal increment was 15.6 6
10.6% (P 5 0.016) with the low dose, 21.0 6 14% (P 5
0.0018) with the intermediate dose, and 47.0 6 7.6%
(P 5 0.024) with the high L-NAME dose.
Renal Water and Sodium Handling
Baseline values of UV, urinary sodium excretion
(UNaV), FENa, and FELi between the four treatment
groups did not differ (Table 2). In the placebo group UV,
UNaV, FENa, and FELi remained stable throughout the
observation period (Fig. 3). In response to the different
doses of L-NAME, UV, UNaV, FENa, and FELi decreased
dose dependently. The relative decrease in FELi was
less pronounced than the decrease in FENa.
Vasoactive Hormones
Baseline values of concentrations of norepinephrine,
active renin, and endothelin-1 in plasma between the
four treatment groups did not differ, but baseline
values of ANP were significantly higher in the group of
subjects receiving the intermediate L-NAME dose com-
pared with the other three treatment groups (Table 3).
In the placebo group, the values of the above-mentioned
parameters remained stable throughout the study. In
response to the low and intermediate doses of L-NAME,
the plasma concentrations of norepinephrine and renin
did not change, whereas these two parameters de-
creased in response to the high L-NAME dose (Table 3).
Plasma concentrations of endothelin-1 and ANP did not
change in response to the three different doses of
L-NAME.
cGMP, L-Citrulline, and Nitrite1Nitrate
Baseline values of plasma cGMP and L-citrulline
between the four treatment groups were similar (Table
3). Values did not change in response to the different
doses of L-NAME.
Baseline values of urinary excretion of cGMP and
nitrite1nitrate between the four treatment groups did
not differ (Table 4). L-NAME infusion was not associ-
ated with a decrease in the urinary excretion of cGMP.
The urinary excretion of nitrite1nitrate moderately
decreased (P , 0.05 vs. change in placebo group) in
response to the high L-NAME dose.
DISCUSSION
This is the first study in men comparing the effects of
different degrees of NO synthesis inhibition by
L-NAME on renal and systemic hemodynamics, sodium
handling, and neurohormones in healthy volunteers.
The different doses of L-NAME induced clearly distin-
guishable effects, both in magnitude and duration, on
systemic and renal hemodynamics, diuresis, and natri-
uresis. With the exception of the highest infusion rate
of L-NAME, increments in RVR and SVR were of
comparable magnitude. These observations therefore
do not support the hypothesis based on animal experi-
ments that the renal vascular bed is more sensitive to
the effects of NO synthesis inhibition than other vascu-
lar beds, but do suggest a comparable basal NO-
mediated vasodilator tone in the renal and systemic
circulation in healthy men.
So far, most NO synthesis inhibition studies per-
formed in healthy volunteers have used NG-mono-
methyl-L-arginine (L-NMMA) as a NO synthase (NOS)
inhibitor (3, 6, 10, 15, 31, 38). In most of these studies, a
maximal dose of 3 mg/kg has been administered as an
extended bolus injection over a 10-min period. With
Table 2. Baseline values of urinary output, sodium
excretion, fractional sodium excretion, and fractional




n 6 6 6 6
UV, ml/min 13.763.2 15.361.7 14.761.8 15.061.8 0.74
UNaV, µmol/min 139670 2536183 2056108 181674 0.74
FENa, % 0.9160.46 1.3260.87 1.2160.64 1.0660.42 0.91
FELi, % 2568 2364 2063 2064 0.09
Values are means 6 SD; n 5 no. of experiments. UV, urinary out-
put; UNaV, urinary sodium excretion; FEx, fractional excretion of ion x.
Fig. 3. Time course of changes in urinary output, sodium excretion,
fractional sodium, and fractional lithium excretion. Percentage
changes compared with baseline are given. Placebo (s) or different
doses of L-NAME (r, as described in legend to Fig. 1) were adminis-
tered by intravenous infusion from 0 to 30 min (shaded area).
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this intravenous dose of L-NMMA, the reported average
rise in MAP ranged from 5 to 10% and the reported
average rise in SVR from 28 to 36%. Similar hemody-
namic effects were observed with the intermediate dose
of L-NAME (0.005 mg·kg21 ·min21 for 30 min, i.e., 0.15
mg/kg in total) that was used in the present study.
From these findings, it can be estimated that, with
respect to its hemodynamic effects, L-NAME is ,20
times more potent than L-NMMA. This fits well with
observations in anesthetized rats, showing that L-NAME
is about 10-fold more potent than L-NMMA in increas-
ing blood pressure and causing bradycardia (25).
L-NAME induced a dose-dependent renal vasocon-
strictor response, confirming previous experimental
and human studies that NO exerts a basal relaxing
effect on the renal circulation (3, 7, 10, 20, 22, 26).
Especially, the highest dose of L-NAME produced pro-
nounced vasoconstriction in the renal circulation, which
exceeded the systemic vasoconstrictor response. If a
predominant NO-mediated vasodilator tone existed in
the renal circulation of our subjects, then we would a
priori expect a more pronounced increase in resistance
in the renal than in the systemic circulation with the
two lowest doses of L-NAME and not just with the
highest dose. Possibly, the divergence in effect of the
highest dose of L-NAME on the renal and systemic
circulation could be explained by autoregulatory adjust-
ment of the renal circulation to the L-NAME-induced
rise in systemic arterial pressure. However, studies in
rats have shown that the renal hemodynamic and
excretory responses to systemic L-NAME infusion were
similar, either when renal perfusion pressure was
allowed to increase (from 122 to 157 mmHg) or when it
was servocontrolled at baseline level (23).
The marked decrements in effective RBF associated
with the various doses of L-NAME were not accompa-
nied by parallel decrements in GFR.Arelative preserva-
tion of GFR after NO synthesis inhibition has been
noticed before (3, 10). Glomerular micropuncture stud-
ies have shown a decrease in glomerular capillary
ultrafiltration coefficient (Kf) in response to either local
or systemic NO synthesis inhibition (8, 40). This de-
crease in Kf appears to be mediated by a rise in
mesangial cell tone (7). The relative preservation of
GFR is therefore likely caused by a rise in the hydro-
static pressure of the glomerular capillaries, indicating
that systemic NO synthesis inhibition elicits more
vasoconstriction in the efferent than in the afferent
arteriole of the glomerulus. Although it is tempting to
speculate that unopposed activity of angiotensin II
underlies this preferential efferent arteriolar vasocon-
striction, this is not supported by our preliminary
observations in losartan-pretreated subjects and by a
recent publication showing that the L-NAME-induced
effects on renal hemodynamics in sodium-repleted
healthy volunteers were not altered by administration
of the angiotensin II receptor blocker losartan (22).
In a dose-response study of L-NAME performed in
anesthetized rats, it was observed that the two lowest
Table 3. Baseline values and time courses of plasma
concentration of norepinephrine, renin, endothelin-1,




n 6 6 6 6
Norepinephrine,
pg/ml
Baseline 1746103 166667 158690 185664 0.95
30 min 1926139 156662 154683 162659
60 min 2056145 167678 165669 122633†
120 min 1936119 186687 146661 123635†
Renin, µU/ml
Baseline 27.864.7 24.7613.8 26.966.1 27.464.0 0.91
30 min 27.565.0 24.7613.9 23.765.9 24.465.3
60 min 27.166.8 24.1617.1 23.367.2 18.663.7†
120 min 27.465.6 22.8614.2 24.066.5 18.763.5†
Endothelin-1,
pg·ml21·ml21
Baseline 4.161.1 3.161.4 3.060.7 5.263.5 0.61
30 min 3.961.3 3.061.1 2.860.9 3.960.6
60 min 3.761.0 3.461.2 3.360.7 4.763.6
120 min 4.363.3 3.061.2 3.061.0 6.266.2
ANP, pg/ml
Baseline 62620 109639 92649 44616 0.015
30 min 62613 103632 95651 42616
60 min 63625 108637 85645 46615
120 min 60617 95625 79643 41610
Values are means 6 SD; n 5 no. of experiments. ANP, atrial
natriuretic peptide. *For differences between baseline values. †P ,
0.05 vs. baseline.
Table 4. Baseline values and time courses of plasma
concentration of cGMP and L-citrulline and urinary
excretion of cGMP and nitrite 1 nitrate




n 6 6 6 6
Plasma cGMP,
pmol/l
Baseline 4.660.7 8.861.3 6.862.2 6.362.1 0.09
30 min 5.060.4 8.561.4 7.062.2 6.561.8
60 min 5.260.9 8.161.2 7.462.2 6.561.8
120 min 4.860.6 8.562.3 6.762.4 6.662.1
Plasma L-citrulline,
µU/ml
Baseline 23.263.5 24.265.9 22.562.7 20.363.1 0.43
30 min 22.161.9 24.664.9 21.462.5 22.766.6
60 min 22.561.8 25.064.6 24.664.0 23.567.9
120 min 22.862.6 25.564.6 23.263.9 22.062.5
Urinary cGMP,
pmol/min
Baseline 365680 5916188 4886248 4166158 0.02
30 min 316691 5436152 4476241 3316130
60 min 280681 5046127 4146230 273669




Baseline 1.860.5 1.160.5 1.660.4 1.760.1 0.06
30 min 1.860.4 1.160.7 1.660.5 1.660.2†
60 min 2.060.4 1.060.5 1.560.3 1.560.4
120 min 2.260.5 1.060.8 1.460.4 1.560.3
Values are means 6 SD. *For differences between baseline values.
†Time course of changes significantly different from placebo time
control study.
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intravenous doses of L-NAME (0.1 and 1.0 µg·kg21 ·
min21 for 3 h) caused an antidiuretic and antinatri-
uretic effect not accompanied by detectable effects on
GFR or RBF (20). This could not be confirmed in the
present study. All three doses of L-NAME applied
caused a decrease in RBF and a rise in FF, but only the
intermediate and high L-NAME doses were associated
with antidiuresis and antinatriuresis. Apparently, in
healthy men, the threshold level of NO synthesis
inhibition to affect renal and sodium water handling is
not lower but appears to be higher than the threshold
level to affect renal hemodynamics.
As evidenced by the pronounced decrease in FENa,
the antinatriuresis observed with the intermediate and
high L-NAME doses was a consequence of increased
tubular sodium reabsorption. The FELi was used as a
marker of proximal tubular sodium reabsorption (4).
Like the FENa, the FELi decreased as well, albeit to a
lesser degree, suggesting that the L-NAME-induced
increase in sodium reabsorption not only occurred in
the proximal tubule of the nephron but also at more
distal nephron sites. Additional evidence that sodium
reabsorption took place beyond the proximal tubule,
particularly in the diluting segment of the nephron, is
provided by the finding that the percentage decrease in
UNaV was far greater than the decrease in UV (Fig. 3).
In vivo studies in rats and dogs have shown that
NO-induced natriuresis can occur independently of
changes in renal hemodynamics (1, 20), indicating that
it is a result of a direct effect of NO on tubular sodium
reabsorption. This is supported by a number of in vitro
studies showing an inhibitory effect of NO on sodium
reabsorption, for example in the proximal tubule (14,
27), the thick ascending limb of Henle’s loop (24), and
the cortical (21, 32, 34) and inner medullary collecting
ducts (40). It cannot be excluded that the antinatriure-
sis observed in the present study was in part caused by
direct effect of L-NAME on tubular sodium reabsorp-
tion. However, the observation that the threshold of
L-NAME to cause changes in renal hemodynamics is
lower than the threshold to cause any decrease in FENa
might be considered in favor of the view that the
antinatriuretic effect currently observed was a conse-
quence of the L-NAME-induced changes in renal hemo-
dynamics.
In an attempt to obtain further information about the
potential mechanisms that underlie the systemic and
renal hemodynamic effects of L-NAME, the time course
of the plasma concentrations of several vasoactive
hormones was monitored. No changes in the plasma
concentrations of norepinephrine, renin, endothelin-1,
or ANP were observed with the low and intermediate
doses of L-NAME. The high L-NAME dose was associ-
ated with moderate decrements in the plasma concen-
trations of norepinephrine and renin. Most likely, the
decrease in plasma norepinephrine was a consequence
of the L-NAME-induced rise in blood pressure and
indicates that acute systemic NO synthesis inhibition
causes a decrease in sympathetic tone. It is well known
that, in addition to the activity of the sympathetic
nervous system, the concentration of norepinephrine in
plasma is determined by its clearance from the intravas-
cular compartment. As a rule, if CO decreases, then so
does the clearance of norepinephrine, and, providing
that sympathetic tone does not change, the plasma
norepinephrine concentration increases. The absence
of a rise in plasma norepinephrine observed with the
low and intermediate doses of L-NAME, despite the
supposed diminishment of its clearance, therefore does
not completely exclude that with these two doses
sympathetic tone was lowered as well.
In vitro studies have provided evidence for either a
stimulatory or an inhibitory effect of NO on renin
secretion (18, 35). In intact animals, acute NO synthe-
sis inhibition with L-NAME is associated with a fall in
plasma renin activity. This fall appears to be mediated
by the L-NAME-induced increase in renal perfusion
pressure and decrease in sympathetic tone, since it is
reversed to a rise when renal perfusion pressure is kept
at a constant level and the stimulatory influence of the
sympathetic nervous system on renin release is abol-
ished by administration of propranolol (30). We there-
fore suggest that the decrease in plasma renin concen-
tration observed with the highest dose of L-NAME has
been mediated by the concomitant increase in arterial
pressure and decrease in sympathetic tone.
It has been shown that, notwithstanding the de-
crease in CO, cardiac filling pressures remained un-
changed during NO synthesis inhibition, suggesting
that withdrawal of the NO vasodilator tone is associ-
ated with both arterial and venous vasoconstriction (6).
The present finding that the plasma ANP concentration
did not increase with the various doses of L-NAME is in
accordance with this view.
Plasma endothelin-1 has been proposed to be the
natural antagonist of NO. There is experimental evi-
dence that blockade of NO synthesis increases tissue
endothelin mRNA expression as well as the plasma
endothelin concentration (5, 17, 26). In the present
study, no change in plasma endothelin concentration
was observed in response to the various L-NAME
infusions. This does not completely exclude that a
change in the production of endothelin has occurred,
since endothelin acts locally and appears to be pre-
dominantly secreted at the abluminal site of the circula-
tion (36).
Since NO is short-lived in vivo, its direct measure-
ment is extremely difficult (13). Instead of measuring
NO, the plasma concentrations of cGMP and L-
citrulline, as well as the urinary excretions of cGMP
and nitrite1nitrate, were used as parameters to moni-
tor the biochemical effects of NO synthesis inhibition.
Despite the marked hemodynamic effects, the plasma
concentrations of cGMP and L-citrulline in response to
the L-NAME infusions did not change. Based on these
findings, we conclude that these parameters, as deter-
mined with the current assays, are not suitable to
monitor the inhibition of constitutive NOS. Unexpect-
edly, considering the pronounced effects on renal hemo-
dynamics, the urinary excretion of cGMP also did not
decrease and the nitrite1nitrate excretion only moder-
ately decreased in response to the high L-NAME dose.
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Possibly, the large amounts of tap water the subjects
had to drink to guarantee a stable urinary flow during
the study may have masked any potential effect of
L-NAME on the urinary excretion of nitrite1nitrate.
The reason for the absence of an effect of L-NAME on
urinary cGMP excretion could be that cGMP production
also depends on other mediators of cellular function
such as ANP. In addition, removal of cGMP from the
renal tubular cells may be preferentially at the basolat-
eral and not at the luminal site of the cell, which limits
the use of urinary cGMP excretion as an index of NO
formation or inhibition (33).
In conclusion, this study further expands our knowl-
edge about the important role of NO in controlling the
vascular tone in both the systemic and renal circulation
in humans. There is no evidence, at least not in healthy
men, that the renal circulation is more sensitive to the
effects of NOS inhibition than the systemic circulation.
Compared with L-NMMA, the most frequently used
NOS inhibitor for performing studies in healthy men,
L-NAME appears to be about 20 times more potent in
inducing systemic and renal hemodynamic effects. We
were intrigued not only about the magnitude but also
about the rather long duration of action of the L-NAME-
induced systemic and renal hemodynamic effects. In
this context, the availability of a simple biochemical
marker by which the degree and duration of NOS
inhibition could easily be monitored would be a valu-
able new tool.
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